Rich LegacyGlorious Future
The JB story is one of passion and performance. Our humble beginnings more than 4 decades ago, set a strong foundation of principles before performance, and a focus on building quality relationships.
This foundation has seen us achieve a lot of significant milestones: from our first international operations, first accreditations, first products to today being India’s fastest growing pharmaceutical company (IQVIA, FY 2020). Our journey is one of consistent growth and delivering value: to patients, healthcare providers, partners, distributors and all stakeholders.
1976
1st brick in the foundation laid by late Mr. J.B. Mody by incorporating JB Chemicals & Pharmaceuticals Laboratories (JBCPL)
1977
Introduced the product Metrogyl, that went on to become the ‘gold standard’ in the industry
1980
Forayed into the cardiac segment with the revolutionary product Nicardia
1985
Got publicly listed and expanded from API to Formulations
1989
Iconic product Rantac introduced
2000
Capitalized on the vast Russia & CIS OT market with 2 Brands: Doktor Mom & Rinza.
2003
Received first FDA approval for our Panoli Plant:T10.
2007
Launched the product Cilacar that went on to become a leading brand in cardiology and nephrology.
2008
Made a strategic investment in a company in South Africa called Biotech Laboratories.
2016
Received a silver award from the United States Pharmacopeia (USP) for participation in the Monograph Development & Upgradation Program and preparation and distribution of USP reference substance
2020
Leading private equity firm Kohlberg Kravis Roberts & Co. Inc. (KKR), acquired a controlling stake of JBCPL.
2021
Ranked 28th in the Industry (ORG- IMS) with 5 brands: Rantac (Anti – Peptic Ulcer ant), Metrogyl (Amebicides), Nicardia ( Calcium Channel Blocker) and Cilacar-T featuring in top 300 brands of the Indian pharmaceutical market.